Last reviewed · How we verify

NCT04347343: COMBO

Combined NMES and BFR Training After TKA

Completed NA Last updated 7 March 2022
What this trial tests

NA trial testing Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction in Total Knee Arthroplasty in 18 participants. Completed in 3 February 2022.

Timeline
22 November 2019
Primary endpoint
3 February 2022
3 February 2022

Quick facts

Lead sponsorUniversity of Colorado, Denver
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment18
Start date22 November 2019
Primary completion3 February 2022
Estimated completion3 February 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 50 to 85, any sex, with Total Knee Arthroplasty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this feasibility study is to determine the initial efficacy of early combined Neuromuscular Electrical Stimulation (NMES) and Blood Flow Restriction (BFR) in addition to standard rehabilitation in 15 subjects after Total Knee Arthroplasty (TKA). The second aim is to determine the feasibility and patient perceptions of combined NMES and BFR by assessing: 1) adherence, 2) satisfaction and 3) safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Total Knee Arthroplasty

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04347343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing